Study finds significant variability in treatment access for patients with malignant pleural mesothelioma
A study of 2,804 patients with stage I to stage III malignant pleural mesothelioma (MPM) found signi...
Durvalumab combined with chemotherapy improves overall survival in patients with lung cancer: First-line treatment reduces mortality risk by 27%
Adding immunotherapy in the form of durvalumab to ...
Discovery of distinct lung cancer pathways may lead to more targeted treatments
Known for its poor prognosis, lung adenocarcinoma ...
